Cognitive Enhancers in Alzheimer’s Disease

  • Neal R. Cutler
  • Prem K. Narang


Cognitive enhancers are compounds that have been purported to improve memory. Several drugs from various classes have been investigated clinically in the elderly population with different types of dementia. It is important to clarify that the dose-response relationships with these agents in the elderly population are almost nonexistent. This difficulty associated with the clinical trials in dementia patients is primarily due to problems related to quantification of the drug effect, as neuropsychological assessments have a large degree of associated measurement error. Pharmacokinetic and dynamic studies with these drugs have been few. Therefore, rather than choosing to discuss kinetics, as expected from the contributions in this part, we have decided to address methodological issues that pertain to all agents being evaluated in the elderly with some form of dementia.


Senile Dementia Cognitive Enhancer Neurochemical Finding Ergoloid Mesylate Glycolytic Pathway Enzyme 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Alzheimer A: Uber eine eigenartige Erkrankung der Hirnrinde. Allg Z Psychiatrie. 1907; 64: 1460–1480.Google Scholar
  2. 2.
    Constantinidis J: Is Alzheimer’s disease a major form of senile dementia? Clinical, anatomical, and genetic data, in Katzman R, Terry RD, Bick KL (eds): Alzheimer’s Disease: Senile Dementia and Related Disorders. New York, Raven Press, 1978, vol 7, pp 15–25.Google Scholar
  3. 3.
    Roth M: Diagnosis of senile and related forms of dementia, in Katzman R, Terry RD, Bick KL (eds): Alzheimer’s Disease: Senile Dementia and Related Disorders. New York, Raven Press, 1978, vol 7, pp 71–85.Google Scholar
  4. 4.
    Petrie WM and Ban TA: Drugs in geropsychiatry. PsychopharmacolBull 1978; 14: 7–19.PubMedGoogle Scholar
  5. 5.
    Salzman C: Stimulants in the elderly, in Raskin A, Robinson DS, Levine J (eds): Age and the Pharmacology of Psychoactive Drugs. New York, Elsevier North Holland Inc, 1981, pp 171–180.Google Scholar
  6. 6.
    Reding MJ, Young R, DiPonte P: Amitriptyline in Alzheimer’s disease. Neurology 1983; 33: 522–523.PubMedGoogle Scholar
  7. 7.
    Cutler NR, Narang PK: Implications of dosing tricyclic antidepressants and benzodiazepines in geriatrics. Psychiatr Clin North Am 1984; 7: 1–17.Google Scholar
  8. 8.
    Hollister LE, Yesavage J: Ergoloid mesylates for senile dementias: Unanswered questions. Ann Intern Med 1984; 100: 894–898.PubMedGoogle Scholar
  9. 9.
    Van Loveren-Huyben CMS, Engelaan HFW, Hermans MBM, Van der Born JA, Leering C, Munnichs JMA: Doubleblind clinical and psychologic study of ergoloid mesylates (Hydergine) in subjects with senile mental deterioration. J Am Geriatr Soc 1984; 32: 584–588.PubMedGoogle Scholar
  10. 10.
    Epstein LJ: Anxiolytics, antidepressants, and neuroleptic patients, in Lipton MA, DiMascio A, Killam KF (eds): Psychopharmacology: A Generation of Progress. New York, Raven Press, 1978, pp 1517–1523.Google Scholar
  11. 11.
    Coyle JT, Price DL, DeLong MR: Alzheimer’s disease: A disorder of cortical cholinergic innervation. Science 1983; 219: 1184–1190.PubMedCrossRefGoogle Scholar
  12. 12.
    Terry RD, Peck A, Deteresa R, Schechter R, Horoupian DS: Some morphometric aspects of the brain in senile dementia of the Alzheimer type. Ann Neurol 1981; 10: 184–192.PubMedCrossRefGoogle Scholar
  13. 13.
    Terry RD, Davies P: Some morphologic and biochemical aspects of Alzheimer’s disease, in Samuel D, Algeri S, Gershon S, Grimm VE, Toffano G (eds): Aging of the Brain. New York, Raven Press, 1983; vol 22, pp 47–59.Google Scholar
  14. 14.
    Carlsson A, Adolfsson R, Aquilonius SM, et al: Biogenic amines in human brain in normal aging, senile dementia, and chronic alcoholism, in Goldstein M, Calne DB, Lieberman A, Thorner MO (eds): Ergot Compounds and Brain Function: Neuroendocrine and Neuropsychiatric Aspects. New York, Raven Press, 1980, pp 295–314.Google Scholar
  15. 15.
    Tomlinson BE, Blessed G, Roth M: Observations on the brains of demented old people. J Neurol Sci 1970; 11: 205–242.PubMedCrossRefGoogle Scholar
  16. 16.
    Yamamoto T, Hirano A: Nucleus raphe dorsalis in Alzhemer’s disease: Neurofibrillary tangles and loss of large cortical neurons. Ann Neurol 1985; 17: 573–77.PubMedCrossRefGoogle Scholar
  17. 17.
    Gottfries OG, Adolfsson R, Aquilonius SM: Biochemical changes in dementia disorders of Alzheimer’s type (AD/SDAT). Neurobiol Aging 1983; 4: 261–271.PubMedCrossRefGoogle Scholar
  18. 18.
    Rossor MN: Neurotransmitters in CNS disease: Dementia. Lancet 1982; 2: 200–204.Google Scholar
  19. 19.
    Iwangoff P, Armbruster R, Enz A, Meier-Ruge W, Sandoz P: Glycolytic enzymes from human autoptic brain cortex: Normally aged and demented cases, in Roberts PJ (ed): Biochemistry of Dementia. London and New York, John Wiley Sons, 1980, pp 258–262.Google Scholar
  20. 20.
    Iwangoff P, Reichlmeier K, Enz A, Meier-Ruge W: Neurochemical findings in physiological aging of the brain. Interdiscipl Topics Gerontol 1979; 15: 13–33.Google Scholar
  21. 21.
    Perry EK, Perry RH: The cholinergic system in Alzheimer’s disease, in Roberts PJ (ed): Biochemistry of Dementia. New York, John Wiley Sons, 1980, pp 135–183.Google Scholar
  22. 22.
    Bartus RT, Dean RL, Beer B, Lippa AS: The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217: 408–417.PubMedCrossRefGoogle Scholar
  23. 23.
    Brinkman SD, Gershon S: Measurement of cholinergic drug effects on memory in Alzheimer’s disease. Neurobiol Aging 1983; 4: 261–271.CrossRefGoogle Scholar
  24. 24.
    Christie JE, Shering A, Ferguson J, Glen AIM: Physostigmine and arecholine: effects of intravenous infusion in Alzheimer presenile dementia. BrJ Psychiatry 1981; 138: 46–50.CrossRefGoogle Scholar
  25. 25.
    Wettstein A, Spiegel R, Koppel-Hefti A: Therapeutic trial with the muscarinic agonist RS-86 in patients with senile dementia of Alzheimer type. Presented at the Collegium Internationale Neuro-Psychopharmacologicum Congress, Florence, Italy, June 18–23, 1983, pp 983.Google Scholar
  26. 26.
    Bruno G, Mohr E, Gillespie MM, Fedio P, Chase TN: RS-86 therapy of Alzheimer’s disease. Neurology 1985; 35 (suppl 1): 265.Google Scholar
  27. 27.
    Zornetzer SF: Neurotransmitter modulation and memory: A new neuropharmacological phrenology? in Lipton MA, DiMascio A, Killam KF (eds): Psychopharmacology: A Generation of Progress. New York, Raven Press, 1978, pp 637–649.Google Scholar
  28. 28.
    Jellinger K, Flament H, Riederer P, Schmid H, Ambrogi L: Levodopa in the treatment of (pre) senile dementia. Mech Aging Dev 1980; 14: 253–264.PubMedCrossRefGoogle Scholar
  29. 29.
    Ferris SH, Reisberg B, Friedman E: Combination cholinepiracetam treatment of senile dementia. Psychopharmacol Bull 1982; 18: 94.Google Scholar
  30. 30.
    Cutler NR, Haxby J, Kay AD, et al: Evaluation of zimelidine in alzheimer’s disease: cognitive and biochemical measures. Arch Neurol 1985; 42: 744–748.PubMedCrossRefGoogle Scholar
  31. 31.
    Davies P, Katzman R, Terry RD: Reduced somatostatinlike immunoreactivity in cerebral cortex from cases of Alzheimer’s disease and Alzheimer senile dementia. Nature 1980; 288: 279–280.PubMedCrossRefGoogle Scholar
  32. 32.
    Rossor MN, Emson PC, Mountjoy CQ, Roth M, Iversen LL: Reduced amounts of immunoreactive somatostatin in the temporal cortex in senile dementia of Alzheimer’s type. Neurosci Lett 1980; 20: 373–377.PubMedCrossRefGoogle Scholar
  33. 33.
    Beal MF, Mazurek MF, Tran VT, Chattha G, Bird ED, Martia JB: Reduced numbers of somatostatin receptors in cerebral cortex in Alzheimer’s disease. Science 1985; 229: 289–291.PubMedCrossRefGoogle Scholar
  34. 34.
    Delfs JR, Zhy CH, Dichter MA: Coexistence of acetylcholinesterase and somatostatinimmunoreactivity in neurons cultured from rat cerebrum. Science 1984; 223: 61–63.PubMedCrossRefGoogle Scholar
  35. 35.
    Ferris SH: Neuropeptides in the treatment of Alzheimer’s disease, in Reisberg B (ed): Alzheimer’s Disease. New York, The Free Press, 1983, pp 369–373.Google Scholar
  36. 36.
    Veber DF, Saperstein R, Nutt RF, et al: A super active cyclic hexapeptide analog of somatostatin. Life Sci 1984; 314: 1371–1378.CrossRefGoogle Scholar
  37. 37.
    Folstein MF, Folstein SE, McHugh PR: Mini-Mental State, a practical method for grading the cognitive state of patients for the clinical. J Psychiatr Res 1975; 12: 189–198.PubMedCrossRefGoogle Scholar
  38. 38.
    Cutler NR, Haxby JV, Narang PK, May C, Burg C, Reines SA: Evaluation of an analogue of somatostatin (L-363,586) in Alzheimer’s disease. N Engl J Med 1985; 312: 725.PubMedGoogle Scholar
  39. 39.
    Kastin AJ, Olson GA, Sandman CA: Possible role of peptides in senile dementia, in: Crook T, Gerson S (eds): Strategies for the Development of an Effective Treatment for Senile Dementia. New Canaan, CT, Mark Powley Associates, 1981, pp 139–152.Google Scholar
  40. 40.
    Reisberg B, Ferris SH, Anand R: Effects of naloxone in senile dementia: a double blind trial. N Engl J Med 1983; 308: 721–722.PubMedCrossRefGoogle Scholar
  41. 41.
    Blass JP, Reding MJ, Drachman E: Cholinesterase inhibitors and opiate antagonists in patients with Alzheimer’s disease. N Engl J Med 1983; 309: 556.CrossRefGoogle Scholar
  42. 42.
    Bjorklund A, Gage FH, Schmidt RH, Stenevi U, Dunnet SB: Intracerebral grafting of neuronal cell suspensions VII. Recovery of choline acetyltransferase activity and acetylcholine synthesis in the denervated hippocampus reinnervated by septal suspension implants. Acta Physiol Scand 1983; (suppl 522 ): 59–66.Google Scholar
  43. 43.
    Rossor MN, Iverson LL, Reynolds GP, Mountjoy CQ, Roth M: Neurochemical characteristics of early and late onset types of Alzheimer’s disease. Br Med 1984; 288: 961–964.CrossRefGoogle Scholar
  44. 44.
    Blessed G, Tomlinson BE, Roth M: The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry 1968; 114: 797–811.PubMedCrossRefGoogle Scholar
  45. 45.
    Mattis S: Mental status examination for organic mental syndrome in the elderly patient, in Bellak L, Katasu T (eds): Geriatric Psychiatry: A Handbook for Psychiatrists and Primary Care Physicians. New York, Grune Stratton, 1976, vol 7, pp 77–121.Google Scholar
  46. 46.
    Thal LJ,Fuld PA, Masur DM, Sharpless NS: Oral physostigmine and lecithin improve memory in Alzheimer’s disease. Ann Neurol 1983; 13:491–495.PubMedCrossRefGoogle Scholar
  47. 47.
    Wettstein A: No effect from doubleblind trial of physostigmine and lecithin in Alzheimer’s disease. Ann Neurol 1983; 13: 210–212.PubMedCrossRefGoogle Scholar
  48. 48.
    Wechsler D: A standardized memory scale for clinical use. J Psychol 1945; 19: 87–95.CrossRefGoogle Scholar
  49. 49.
    Benton AC: The Revised Visual Retention Test, New York, Psychological Corporation, 1974.Google Scholar
  50. 50.
    Benson DF: Aphasia, in Heilman EM, Valenstein E (eds): Clinical Neuropsychology. New York, Oxford University Press, 1979, pp 22–58.Google Scholar

Copyright information

© Plenum Publishing Corporation 1986

Authors and Affiliations

  • Neal R. Cutler
    • 1
  • Prem K. Narang
    • 2
  1. 1.Department of Geriatrics, Cedars-Sinai Medical CenterUniversity of California-Los Angeles School of MedicineLos AngelesUSA
  2. 2.Clinical Pharmacokinetics Research Laboratory, Pharmacy Department, Clinical CenterNational Institutes of HealthBethesdaUSA

Personalised recommendations